PRESS-RELEASE ·Filed Mar 18, 2026

XOMA

XOMA Royalty Corporation
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago WireGlobeNewswire
Press release: dividend
Actionable Insight • Neutral

Preferred shareholders will receive scheduled dividends; no implication for common stock dividend or capital allocation shift. Monitor for any future changes in payout policy or portfolio monetization events that could affect cash flow.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
XOMA ▲ +45.31% at T+60d
NEUTRAL call ✓ call won +45.31% · α vs SPY +30.96% · entry $28.76 → $41.79
Entry anchored
Mar 18, 03:59 PM ET
via exchange tick
T+1d
-0.17%
call -0.17% · α +1.57%
$28.71
settled 7mo ago
T+5d
+6.15%
call +6.15% · α +8.37%
$30.53
settled 6mo ago
T+20d
+38.07%
call +38.07% · α +30.45%
$39.71
settled 6mo ago
T+60d
+45.31%
call +45.31% · α +30.96%
$41.79
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

XOMA Royalty Corporation declared quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock, with $0.53906 per share for Series A and $0.52344 per depositary share for Series B, payable April 15, 2026, to holders of record on April 2, 2026. This is a routine dividend announcement with no change in policy or magnitude.

Key Facts

  • XOMA declared cash dividends on Series A and Series B Preferred Stock
  • Series A dividend: $0.53906 per share
  • Series B dividend: $0.52344 per depositary share (each representing 1/1000 of a preferred share)
  • Dividends payable April 15, 2026, to holders of record as of April 2, 2026
  • No change in dividend amount or policy indicated

Financial Impact

Routine quarterly preferred dividends; no material impact on common equity or balance sheet disclosed

dividend_paymentcash_outflow

Risk Factors

  • Preferred dividends are cumulative; failure to pay would result in arrears and could restrict future distributions to common shareholders
  • No update on common stock dividend policy or portfolio performance provided

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258617
8 reports for XOMA
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +52.83%Mar 18, 2026
Filters
Rows
Reports for XOMA — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
BEARISH ★ 7/10
—awaiting T+5——
Jul 14, 2026
11w ago
8-K
BULLISH ★ 8/10
$40.17 $40.17· 0.00%▲ +0.47%$163.54 (+307.12%)
Jun 12, 2026
15w ago
DEFA14A
BULLISH ★ 8/10
$41.95 $42.00▲ +0.12%▲ +1.50%$163.54 (+289.85%)
Jun 12, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$41.95 $42.00▲ +0.12%▲ +1.50%$163.54 (+289.85%)
Mar 18, 2026
28w ago
Press Release
NEUTRAL ★ 3/10
$28.76 $30.53▲ +6.15%▲ +8.37%$163.54 (+468.64%)
Mar 18, 2026
28w ago
8-K
NEUTRAL ★ 4/10
$27.35 $30.20▲ +10.42%▲ +11.14%$163.54 (+497.95%)
Mar 18, 2026
28w ago
Press Release
BULLISH ★ 8/10
$27.35 $30.20▲ +10.42%▲ +11.14%$163.54 (+497.95%)
Mar 12, 2026
29w ago
Press Release
NEUTRAL ★ 3/10
$26.86 $28.76▲ +7.07%▲ +8.05%$163.54 (+508.86%)
Showing 8 of 8

US Market Status

Market Open — Closes in 3h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 18, 2026